Intrexon’s Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference

On June 13, 2019 Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its wholly-owned Intrexon Health subsidiary Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, reported their presentation at the JMP Securities Life Sciences Conference in New York. Helen Sabzevari, PhD, President of Precigen, will highlight Intrexon Health and Precigen in the presentation on Thursday, June 20, 2019 at 12:30 pm Eastern Time (Press release, Intrexon, JUN 13, 2019, View Source [SID1234537068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors section of Intrexon’s website under ‘Events’ at investors.dna.com/events and on Precigen’s website under ‘Presentations’ at www.precigen.com/media/#id-presentations. The presentation will be archived on the Intrexon and Precigen websites for 30 days following the event.

BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference

On June 13, 2019 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, reported that its Chief Executive Officer, Philip Serlin, will present a company update at the JMP Securities 2019 Life Sciences Conference on Wednesday, June 19, 2019 at 2:00 p.m. (EDT) (Press release, BioLineRx, JUN 13, 2019, View Source [SID1234537067]). The conference will be held at the St. Regis New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on BioLineRx’s website. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15

On June 13, 2019 Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, reported that ELZONRIS (tagraxofusp) is the subject of three clinical presentations at the Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) (Press release, Stemline Therapeutics, JUN 13, 2019, View Source [SID1234537065]). Data from the ongoing Phase 1/2 trials in chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), as well as the results from the pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN) will be delivered via poster presentation at the 24thCongress of the European Hematology Association (EHA) (Free EHA Whitepaper) in Amsterdam, Netherlands.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ELZONRIS (tagraxofusp) is FDA-approved for the treatment of patients, adults and pediatric 2 years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN), and is commercially available in the U.S.

Details on the presentations are listed below. Presentations will be available on the Stemline website (www.stemline.com) Scientific Presentations tab, after their delivery.

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocitic Leukemia (CMML)

• Abstract: PF672
• Presenter: Mrinal M. Patnaik, MBBS; Mayo Clinic
• Date: Friday, June 14
• Time: 5:30 – 7:00 PM CET
• Location: Poster Area

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis (MF)

• Abstract: PF668
• Presenter: Naveen Pemmaraju, MD; The University of Texas MD Anderson Cancer Center
• Date: Friday, June 14
• Time: 5:30 – 7:00 PM CET
• Location: Poster Area

Results of the Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

• Abstract: PS1063
• Presenter: Naveen Pemmaraju, MD; The University of Texas MD Anderson Cancer Center
• Date: Saturday, June 15
• Time: 5:30 – 7:00 PM CET
• Location: Poster Area
Please visit the BPDCN disease awareness booth (#1351) during the 24thCongress of EHA (Free EHA Whitepaper).

About ELZONRIS
ELZONRIS (tagraxofusp-erzs), a CD123-directed cytotoxin, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). For full prescribing information in the U.S., visit www.ELZONRIS.com. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in additional clinical trials in other indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute myeloid leukemia (AML).

About BPDCN
BPDCN is an aggressive hematologic malignancy with historically poor outcomes and an area of unmet medical need. BPDCN typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. For more information, please visit the BPDCN disease awareness website at www.bpdcninfo.com.

About CD123
CD123 is a cell surface target expressed on a wide range of myeloid tumors including blastic plasmacytoid dendritic cell neoplasm (BPDCN), certain myeloproliferative neoplasms (MPNs) including chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), acute myeloid leukemia (AML) (and potentially enriched in certain AML subsets), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). CD123 has also been reported on certain lymphoid malignancies including multiple myeloma (MM), acute lymphoid leukemia (ALL), hairy cell leukemia (HCL), Hodgkin’s lymphoma (HL), and certain Non-Hodgkin’s lymphomas (NHL). In addition, CD123 has been detected on some solid tumors as well as autoimmune disorders including cutaneous lupus and scleroderma.

OncoSec to Present Immunological Data at World Pharma Week 2019

On June 13, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported that Christopher G. Twitty, Ph.D., Chief Scientific Officer, will present compelling immunological data from multiple clinical trials using the Company’s novel biomarker technology at World Pharma Week (WPW) 2019 taking place June 17-20 in Boston (Press release, OncoSec Medical, JUN 13, 2019, View Source [SID1234537064]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Twitty’s presentation, titled "Reversing Resistance to Definitive Anti-PD-1 Failures with Intratumoral IL-12 and Pembrolizumab Combination Therapy," will focus on approaches to overcome immune resistance mechanisms in cancer, namely reinvigorating T cell exhaustion with DNA-based cytokines, chemokines and T cell engaging antibodies.

Specifically, Dr. Twitty’s presentation will highlight:

Immunological data from OncoSec’s biomarker program taken from the OMS-102, KEYNOTE-695 (metastatic melanoma), and KEYNOTE-890 (metastatic triple negative breast cancer) clinical studies;
Developments associated with OncoSec’s visceral lesion applicator (VLA) and its next-generation plasmids;
Therapeutic rationale for intratumoral delivery of IL-12 for treatment across multiple solid tumor types.
The presentation will be made during the Combinations Strategies and Clinical Trials in Immuno-Oncology track, which is part of Cambridge Healthtech Institute’s Third Annual Clinical Innovation for Combination Immunotherapy meeting. A link to the meeting’s agenda and speaker panel can be found here.

With more than 1,500 senior delegates and 130 exhibitors slated for this year’s conference, WPW attracts renowned experts across the global medical sciences community and is dedicated to all stages of pharmaceutical R&D, from discovery though preclinical development and translational research to clinical biomarkers.

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20

On June 13, 2019 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) reported that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:00 p.m. EDT in New York City (Press release, CTI BioPharma, JUN 13, 2019, View Source;p=RssLanding&cat=news&id=2401339 [SID1234537063]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Event:

JMP Securities Life Sciences Conference

Date:

Thursday, Jun. 20

Time:

2:00 p.m. EDT